Does Aspirin Prevent Stroke? What the Evidence Shows

Aspirin’s ability to prevent stroke depends almost entirely on whether you have already had one. For people who have experienced a stroke or a transient ischemic attack (a “mini-stroke”), daily low-dose aspirin is one of the most effective and inexpensive tools available, cutting the risk of another ischemic stroke by a substantial margin. For people who have never had a stroke or heart attack, the picture is far less encouraging: the small reduction in ischemic stroke risk is roughly offset by an increased risk of bleeding, including bleeding in the brain. That distinction between “secondary prevention” (after a stroke) and “primary prevention” (before one) is the single most important thing to understand about aspirin and stroke.

How Aspirin Interferes With Clot Formation

When a blood vessel wall is damaged, platelets clump together and form a clot. Aspirin blocks an enzyme involved in producing thromboxane A2, a chemical signal that tells platelets to aggregate. With less thromboxane around, platelets are less sticky, and dangerous clots are less likely to form on damaged artery walls.¹ That same anti-clotting property, though, means that when bleeding does occur anywhere in the body, it takes longer to stop. Every benefit aspirin provides against clot-driven (ischemic) strokes has to be weighed against a somewhat higher chance of bleeding-driven (hemorrhagic) strokes and gastrointestinal hemorrhage.

Primary Prevention in Healthy People

If you have never had a heart attack or stroke and you are otherwise healthy, the case for taking daily aspirin is weak. A large pooled analysis of 11 trials covering more than 134,000 people found that low-dose aspirin modestly reduced the risk of nonfatal heart attacks and nonfatal ischemic strokes, but had no significant effect on fatal strokes, fatal heart attacks, cardiovascular death, or death from any cause over roughly four to ten years of follow-up.² A meta-analysis focused specifically on stroke in people without cardiovascular disease calculated the net clinical benefit of aspirin and found it was essentially zero: the small reductions in nonfatal strokes and heart attacks were counterbalanced by increases in major gastrointestinal bleeding and hemorrhagic stroke.³

That net-zero calculation has shifted guidelines sharply. The benefit of low-dose aspirin for primary prevention is marginal and must be carefully weighed against the well-established excess risk of major bleeding.⁴ A broader summary of the evidence puts it bluntly: in large population settings, aspirin’s benefit does not outweigh its risk for primary cardiovascular disease prevention.⁵

After a Stroke or TIA

The evidence flips dramatically once someone has already had an ischemic stroke or TIA. Aspirin reduces the relative risk of recurrent stroke, heart attack, and death from vascular causes in these patients.⁶ When aspirin is started soon after a first stroke or TIA, the benefits are especially striking. In a pooled analysis of individual patient data, aspirin reduced the six-week risk of another ischemic stroke by about 60%, and the risk of a disabling or fatal ischemic stroke by about 70%.⁷ Those numbers are large, and the greatest benefit was seen in people who presented with a TIA or minor stroke, where early aspirin nearly eliminated the risk of a disabling follow-up stroke in the first two weeks.

Aspirin in the First 48 Hours After a Stroke

When an acute ischemic stroke happens, aspirin given within the first day or two is a standard part of treatment. A combined analysis of about 40,000 patients from two major acute stroke trials found that early aspirin reduced recurrent ischemic stroke by about seven per thousand patients and reduced the combined risk of death or further stroke in the hospital by about nine per thousand, even after accounting for a small increase in hemorrhagic events.⁸ Another large trial of 20,000 patients with acute ischemic stroke showed a significant 14% reduction in death during the treatment period and fewer recurrent ischemic strokes in the aspirin group, with only a slight, nonsignificant increase in hemorrhagic strokes.⁹

The evidence for acute-phase aspirin is solid enough that it has become part of standard protocols around the world. It is typically given as soon as a hemorrhagic stroke has been ruled out by imaging.

Adding a Second Antiplatelet Drug

For people who have just had a minor ischemic stroke or a high-risk TIA, doctors often add clopidogrel to aspirin for a short period rather than using aspirin alone. A systematic review and meta-analysis found that starting dual therapy within 24 hours of symptom onset cut the risk of nonfatal recurrent stroke by about 30% compared with aspirin alone, without a significant increase in death, though there was a small increase in moderate-to-severe bleeding outside the brain.¹⁰ The key, however, is keeping that dual therapy short. Extending it beyond about a month raises bleeding risk without adding much benefit. A meta-analysis of randomized trials confirmed that short-duration dual therapy started during the early acute phase was associated with less bleeding than longer courses and still provided greater reduction in recurrent strokes compared with aspirin alone.¹¹

A subgroup analysis of a large randomized trial even suggested that starting clopidogrel-plus-aspirin between 48 and 72 hours after symptom onset may reduce the risk of new stroke at 90 days by about 30% compared to aspirin alone.¹² That finding reinforces current practice: a brief course of two antiplatelet drugs after a minor stroke or TIA, then transition to a single drug long-term.

Why Aspirin Works Differently in Women and Men

One of the more surprising findings in aspirin research is that the drug’s preventive effects differ by sex. In a meta-analysis of over 95,000 people in primary prevention trials, aspirin reduced the risk of ischemic stroke in women by about 24% but had no significant effect on heart attacks in women. In men, the pattern reversed: aspirin cut the risk of heart attacks by about 32% but did not significantly reduce stroke.¹³

A more recent meta-analysis with a specific focus on stroke confirmed this pattern: in women, aspirin significantly reduced overall stroke risk and ischemic stroke risk compared with placebo, whereas in men, aspirin had no significant effect on stroke and was associated with a borderline increase in hemorrhagic stroke risk. Aspirin significantly increased major bleeding in both sexes.¹⁴ Older guidelines from the U.S. Preventive Services Task Force actually reflected this sex difference, recommending aspirin for women aged 55 to 79 specifically when the potential benefit of stroke reduction outweighed bleeding risk, while for men it was recommended based on heart attack reduction.¹⁵ More recent guidelines have moved away from recommending aspirin for most primary prevention patients regardless of sex, but the biological difference remains noteworthy.

Older Adults Face a Worse Trade-Off

The risk-benefit balance of aspirin tilts particularly unfavorably in otherwise healthy older adults. The ASPREE trial enrolled more than 19,000 people aged 70 and over (or 65 and over for Black and Hispanic participants in the United States) who had no prior cardiovascular events. After a median follow-up of about five years, aspirin did not reduce cardiovascular events: the rate was about 10.7 per thousand person-years on aspirin versus 11.3 on placebo, a nonsignificant difference.¹⁶ Meanwhile, major hemorrhage was significantly more common in the aspirin group, at 8.6 events per thousand person-years versus 6.2 on placebo.

The most concerning finding was that all-cause death was actually higher in the aspirin group, driven primarily by an excess of cancer-related deaths. Cancer death occurred in about 3.1% of the aspirin group versus 2.3% of the placebo group.¹⁷ That cancer signal was unexpected and remains under investigation, but it reinforced the takeaway that aspirin should not be started casually in healthy older people. A secondary analysis of the same trial looking specifically at stroke found that aspirin did not significantly reduce ischemic stroke in this population but did significantly increase intracranial bleeding, particularly in people prone to falls.¹⁸

Diabetes and the Bleeding Balancing Act

People with diabetes face a higher risk of heart attacks and strokes, which in theory should make aspirin more worthwhile for them. In practice, the gains and losses still roughly cancel out. The ASCEND trial, a large study of more than 15,000 people with diabetes and no prior cardiovascular disease, found that aspirin significantly reduced serious vascular events, but major bleeding events rose by a similar margin. The investigators concluded that the absolute benefits were largely counterbalanced by the bleeding hazard.¹⁹

A meta-analysis that pooled data from multiple trials in people with diabetes found a significant reduction in major cardiovascular events and noted a significant reduction in stroke for aspirin doses at or below 100 mg per day, without a statistically significant increase in major bleeding.²⁰ But a more recent analysis of high-risk patients with type 2 diabetes from the ACCORD trial found no reduction in cardiovascular events or death with aspirin use.²¹ The overall picture for diabetes remains unsettled: some benefit exists, but it’s modest and comes with real bleeding risk, making the decision highly individual.

Atrial Fibrillation Requires More Than Aspirin

One common misconception is that aspirin can protect against stroke in people with atrial fibrillation. Atrial fibrillation causes blood to pool and clot in the heart’s upper chambers, and those clots can travel to the brain. Aspirin is far less effective at preventing these embolic strokes than anticoagulant drugs are. An individual-patient meta-analysis found that oral anticoagulants roughly halved the rate of ischemic stroke compared to aspirin, with stroke rates of about 2.4 per hundred patient-years on anticoagulants versus 4.5 on aspirin.²² Well-managed anticoagulant therapy is roughly twice as effective as aspirin at preventing stroke in atrial fibrillation.²³ With newer direct oral anticoagulants now widely available, aspirin is no longer considered appropriate for stroke prevention in most people with atrial fibrillation.

The Bleeding Risks in Context

The hemorrhagic stroke risk from aspirin is real but small. A review of primary and secondary prevention studies estimated that aspirin increases the risk of hemorrhagic stroke by about 0.2 events per thousand patient-years.²⁴ A systematic review of observational studies looking at intracranial hemorrhage with long-term low-dose aspirin found mixed results across seven studies, with an overall pooled risk ratio of about 1.4, meaning a modest increase that was not consistently statistically significant across study designs.²⁵

Gastrointestinal bleeding is more common than brain bleeding and is the main driver of aspirin’s harm. For people who need aspirin (or dual antiplatelet therapy) and are at elevated risk of stomach ulcers or GI bleeding, proton pump inhibitors can substantially reduce that risk. A meta-analysis found that proton pump inhibitors reduced the odds of aspirin-related upper GI ulcers by about 84% and the odds of GI bleeding by about 73%, without increasing cardiovascular events.²⁶ A separate trial confirmed that proton pump inhibitors reduced GI events regardless of aspirin dose in patients on dual antiplatelet therapy.²⁷ If you take aspirin long-term and have a history of stomach problems or are on other drugs that irritate the stomach, a conversation with your doctor about adding a proton pump inhibitor is worthwhile.

Aspirin Resistance

Not everyone who takes aspirin gets the expected antiplatelet effect. Estimates of “aspirin resistance,” defined as inadequate platelet suppression despite regular use, hover around 20 to 25% in stroke patients. A systematic review and meta-analysis found that the pooled prevalence of high on-treatment platelet reactivity to aspirin in ischemic stroke patients was about 23%, and patients with this high residual platelet activity had roughly an 80% higher risk of recurrent ischemic stroke or TIA.²⁸ One study of Chinese stroke patients found that about a fifth tested resistant to aspirin, and that diabetes and high LDL cholesterol were independent risk factors for resistance.²⁹

Despite the existence of platelet function tests, routine testing for aspirin resistance is not standard practice. Part of the problem is that different assays define resistance differently, making it hard to compare results or establish thresholds.³⁰ Researchers have proposed a “platelet-guided” approach to antiplatelet therapy, where test results would determine which drug and dose each patient receives, but this remains largely investigational.

Clopidogrel Versus Aspirin for Long-Term Secondary Prevention

After the short-duration dual antiplatelet window closes, patients are typically maintained on a single antiplatelet drug. A meta-analysis found that clopidogrel monotherapy reduced the risk of major cardiovascular and cerebrovascular events by about 28%, recurrent ischemic stroke by about 28%, and bleeding events by about 43% compared with aspirin monotherapy after a recent ischemic stroke, with no difference in all-cause death.³¹ A real-world comparison of the two drugs, however, found comparable rates of recurrent stroke, although mortality was somewhat higher in the clopidogrel group.³² In people with type 2 diabetes specifically, a meta-analysis found no significant difference between aspirin and clopidogrel for recurrent stroke, hemorrhage, heart attacks, or death.³³

The choice between aspirin and clopidogrel for long-term use depends on individual factors including tolerance, cost, bleeding history, and whether the patient shows signs of resistance to one drug or the other. Aspirin remains the first-line default in many settings largely because of its low cost and long track record, but clopidogrel is a reasonable alternative.

Dose Matters Less Than You’d Think

In secondary prevention, the most commonly used aspirin doses range from 75 mg to 325 mg daily. A secondary analysis of the ADAPTABLE trial, which directly compared 81 mg and 325 mg in patients with established cardiovascular disease, found no significant difference in effectiveness or safety between the two doses in either men or women.³⁴ An earlier review reached a similar conclusion, noting that across the low-dose range of 75 to 325 mg, evidence did not clearly favor any single dose for either effectiveness or safety.³⁵

Interestingly, when aspirin is combined with clopidogrel after a minor stroke or TIA, higher aspirin doses may actually be worse. An analysis from the POINT trial found that aspirin doses above 100 mg per day, when combined with clopidogrel, were associated with a significantly higher risk of ischemic stroke and the composite endpoint of stroke, heart attack, or death compared with doses at or below 100 mg, with no difference in hemorrhagic complications between the groups.³⁶ The takeaway: when on dual therapy, lower aspirin doses appear safer and potentially more effective.

Why You Shouldn’t Stop Aspirin on Your Own

People sometimes stop taking aspirin before surgery, because of side effects, or simply because they forget to refill a prescription. There is evidence that abruptly discontinuing aspirin after chronic use can trigger a rebound increase in clotting risk. One study found that the risk of ischemic stroke tripled in the four weeks after aspirin was stopped in patients with multiple cerebrovascular risk factors.³⁷ Experimental work suggests that after aspirin is withdrawn, a new population of platelets emerges with heightened clotting activity, creating a temporary prothrombotic window.³⁸ Complications tend to occur within the first month after stopping. If you need to discontinue aspirin for any reason, the decision should be made with your doctor, who can weigh the surgical or procedural risk against the rebound clotting risk.

Inappropriate Use Remains Common

Despite the shift in guidelines away from routine aspirin for primary prevention, many people continue taking it without a clear indication. A pharmacist-led quality improvement study found that nearly a quarter of older patients reviewed were taking aspirin inappropriately, meaning they had no established cardiovascular disease and no other strong indication. After the implementation of a deprescribing protocol, the rate of inappropriate use dropped modestly but significantly. The finding underscores a practical reality: guidelines change faster than prescribing habits, and many people who started aspirin years ago under older recommendations have never been reassessed.

If you are taking a daily aspirin because you were told to years ago, and you have never had a stroke, heart attack, or stent placed, it is worth asking your doctor whether the recommendation still applies to you. The evidence is clear that aspirin saves lives and prevents disability in people who have already experienced a clot-driven vascular event. For everyone else, the math has changed.